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Abstract
Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show
sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated
the patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour
infusion. Methods: A total of 243 patients with ID were randomized alternatively to receive iron
polymaltose infusion either as a 2-hour infusion or as a 4-hour infusion. All patients received premedication with certizine hydrochloride 10 mg PO one-hour before infusion and hydrocortisone 50 mg IVI
immediately before infusion. Infusion related adverse events/side-effects during the infusion and over the
next seven days were documented and graded as mild, moderate or severe. Results: The age of the
patients ranged from 17 years to 92 years (mean 55.5 yr); M:F = 1:3.5. One hundred and twenty-two
patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were in the 4-hour arm (M:F = 1:2.6;
mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients in both arms. Adverse
events/side effects were documented in 14 patients in each arm (22 events in the 2-hour arm and 20 in
the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal cramps,
rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild
and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron
polymaltose is similar to that observed with 4-hour infusion of iron polymaltose.
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ABSTRACT
Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show
sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated the
patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour infusion. Methods: A total of 243 patients with ID were randomized alternatively to receive iron polymaltose infusion either as
a 2-hour infusion or as a 4-hour infusion. All patients received pre-medication with certizine hydrochloride 10
mg PO one-hour before infusion and hydrocortisone 50 mg IVI immediately before infusion. Infusion related
adverse events/side-effects during the infusion and over the next seven days were documented and graded as
mild, moderate or severe. Results: The age of the patients ranged from 17 years to 92 years (mean 55.5 yr); M:F =
1:3.5. One hundred and twenty-two patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were
in the 4-hour arm (M:F = 1:2.6; mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients
in both arms. Adverse events/side effects were documented in 14 patients in each arm (22 events in the 2-hour
arm and 20 in the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal
cramps, rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild
and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron polymaltose is similar to that observed with 4-hour infusion of iron polymaltose.
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1. Introduction
Iron deficiency (ID) state, with or without anaemia, is a
common problem worldwide afflicting all age groups for
varying reasons. [1] Optimum management of patients
with ID requires identification and treatment of the cause,
as well as iron supplementation therapy, the latter generally given orally. However, there are several practical
problems with oral iron therapy, e.g. gastro-intestinal
side effects, poor absorption and poor patient compliance.
[2] Patients with one or more of these problems are candidates for consideration of parenteral iron therapy. Sev*
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eral recent reports have documented the efficacy and
safety of total dose intravenous iron infusion therapy,
making it the preferred parenteral route [3-5]. In Australia iron polymaltose is the only agent currently PBS
(pharmaceutical benefit scheme) listed, given mostly as a
4-hour infusion. [5,6] In the present study, we have
compared the safety and patient tolerance of 2-hour versus 4-hour infusion of total dose iron polymaltose in 243
patients.

2. Material and Methods
During a six month period (April-September, 2012) 243
IJCM
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patients with proven ID and deemed unsuitable for oral
iron therapy were randomized to receive total dose (500
mg - 1000 mg) iron polymaltose intravenous therapy
either as a 2-hour infusion or as a 4-hour infusion. The
patients had been referred to one of the Consultant Clinical Haematologists for assessment and consideration of
parenteral iron supplementation therapy. The rationale
for the study was discussed with each patient by the
Consultant Clinical Haematologist and the patients who
had agreed to participate were randomized alternatively
to the 2-hour arm or the 4-hour arm on the day of treatment by a reception staff member of the treating day care
centre. Patients with the following medical history/problems were excluded from the study: hypersensitivity to
iron, first trimester of pregnancy, severe inflammatory
bowel disease, severe renal or liver disease, heart failure,
bronchial asthma, history of severe allergic reactions and
impending or recent surgery. The study was approved by
the Human Resources Ethics Committee, University of
Wollongong (HE 12/88) and all the participating patients
had signed the required consent form.
Patients were routinely given pre-medication with certizine hydrochloride 10 mg PO one hour before the infusion and hydrocortisone 50 mg IVI immediately before
commencement of the infusion. Iron polymaltose (500
mg - 1000 mg) was diluted in 500 ml of normal saline
and the infusion was commenced at 50 mls per hour for
10 minutes in all patients. After ensuring that there are no
anaphylactic reactions, the rate of infusion was increased
to 125 mls per hour for patients in the 4-hour group; and,
to 250 mls per hour for patients in the 2-hour group.
They were closely monitored with periodic pulse and
blood pressure measurements and for hypersensitivity
reactions such as urticarial rash, itching, nausea and fever
or shivering.
The nursing staff in the treating day care centre closely
monitored the patients during the infusion and documented any adverse events. Subsequently, the patients
were contacted one and seven days after the infusion to
obtain information of possible delayed reactions: fever,
arthralgia, myalgia, light headedness, headache, metallic
taste, nausea, vomiting, diarrhoea and rash. The adverse
events during and after the infusion were graded as mild
(no observable patient discomfort/no activity limitation),
moderate (observable patient discomfort/some activity
limitation) or severe (distress or requiring medical assistance) [7].

3. Results
A total of 243 patients were recruited over a six month
period from two centres (Sydney and Wollongong). The
age of the patients ranged from 17 years to 92 years
(mean 55.5 yr); M:F = 1:3.5. One hundred and twentyOPEN ACCESS

two patients (M:F = 1:5; mean age 52.9 yr) received the
iron infusion over a 2-hour period, whilst the other 121
patients (M:F = 1:2.6; mean age 58.1 yr) received the
infusion over a 4-hour period. Iron infusion therapy was
generally well tolerated and the majority of patients (in
both arms) who returned to the clinical haematologists
for follow-up reported an improved sense of wellbeing l 7 days after the infusion.
The reported side-effects/adverse events in the 2-hour
infusion arm and the 4-hour infusion arm are shown in
Table 1. Fourteen of the 122 patients in the 2-hour infusion arm reported 22 side-effects/adverse events. Some
of the side-effects (aches and pains, cannula-site pain/
swelling, nausea and abdominal cramps) lasted for more
than 24 hours, whilst the others (rash, vagal response and
metallic taste) were transient, lasting for less than one
hour. In 12 of the 14 patients, the side-effects were mild;
two patients had moderate aches and pains. None had
any severe side-effects.
Table 1. Reports of adverse events.
2-Hour infusion:
14/122 patients

4-Hour infusion:
14/121 patients

Mild Moderate Severe Mild Moderate Severe
All

20

2

0

During
infusion
Aches and
pains
Hot flushes
Rash

1

0

0

Vagal
response

1

0

0

24 Hrs
post-infusion
Abdominal
cramps

17

3

0

2

0

0

1

0

0

1

0

0

1

0

0

Aches and
pains

5

1

0

2

0

0

Cannula site
pain/swelling

1

0

0

1

1

0

2

0

0

Metallic taste

2

0

0

Nausea

2

0

0

1

0

0

Aches and
pains

5

1

0

4

1

0

Cannula site
pain/swelling

1

0

0

1

1

0

2

0

0

1

0

0

Headache

Day 1-7
post-infusion
Abdominal
cramps

Headache
Nausea
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Fourteen of the 121 patients in the 4-hour infusion arm
reported 20 side effects (Table 1). None of the side-effects was severe. Hot flushes, vagal response and abdominal cramps were mild and transient. Aches and
pains lasted for less than 24 hours in two patients. In five
patients this symptom lasted for more than 24 hours; in
one of these patients this symptom was graded as “moderate”. Two patients had cannula site pain and swelling
which lasted for more than 24 hours; one “mild” and one
“moderate”. Two patients reported headache lasting for
more than 24 hours—one “mild”, one “moderate”.

4. Discussion
Iron polymaltose therapy was well tolerated and the
overall incidence of adverse events/side effects was low.
There was no significant difference between the 2-hour
infusion group and the 4-hour infusion group. In most of
the patients (12/14, 11/14, respectively) the side-effects
were mild; none had any severe side-effects. As the study
was specifically designed to assess and compare the
safety and patient tolerance and, a large proportion of the
patients who participated in the study had returned to
their regular medical practitioners for on-going care, data
relating to the efficacy of iron polymaltose infusion were
not routinely collected.
Our experience with the 2-hour infusion of iron polymaltose is comparable to that reported by Garg et al. [7]
The latter authors administered iron polymaltose as a
58-minute infusion after an initial 15-minute test dose
without pre-medication to 100 patients and documented
34 side-effects in 24 patients during infusion and 31 sideeffects in 26 patients during the 5-day post-infusion period. The presence of inflammatory bowel disease was
associated with a higher incidence of side-effects during
the infusion. None of the patients in our study had severe
inflammatory bowel disease and they were routinely
given pre-medication with cetirizine hydrochloride orally
(one hour before infusion) and hydrocortisone IVI (immediately before infusion). These two differences may
explain the lower incidence of side-effects documented
in our study. However, we note that the potential beneficial role of pre-medication is controversial. A retrospective study of 386 patients by Newnham et al. [8] had
shown no difference in the incidence of adverse events in
patients receiving premedication (92 patients) compared
to those (294 patients) who did not receive pre-medication.
Iron carboxymaltose (Ferric carboxymaltose) is another iron preparation which can be used for intravenous
infusion therapy. This product can be given as a highdose (500 mg - 1000 mg) drip infusion over a 15 minute
period. Although currently available in Australia, this
product is not in the Pharmaceutical Benefit Scheme
OPEN ACCESS
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(PBS) list and so, is more expensive ($176.95 for 500 mg)
than iron polymaltose ($50.36 for 500 mg) [9]. The reported side-effects with iron carboxymaltose infusion are
similar to those documented with iron polymaltose infusion: headaches, nausea, rash, dizziness, local injection
site reactions, abdominal pain, diarrhoea and vomiting
[10].
To the best of our knowledge, there are no reported
studies comparing the rate of adverse events/side-effects
between iron polymaltose infusion and iron carboxymaltose infusion. There are also no randomized studies to
assess the benefits of pre-medication in patients receiving
total dose iron infusion therapy. These reservations notwithstanding, the cumulative experience to date, has led
to widespread and increasing use of total-dose iron infusion therapy as an effective, convenient and well-tolerated alternative for patients with ID who are deemed to
be in need of parenteral iron therapy [11,12]. Infusions
over shorter periods will enable Day Care Centres to treat
more patients, thus reducing the patient waiting time and
also making the treatment more cost-effective.
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